Bruker has postponed reporting of its final Q4 and full-year 2019 results, but reported preliminary Q4 revenues of $599.9 million and full-year revenues of $2.07 billion.
Gladstone Institutes researchers will use proteomic, genomic, and gene-altering approaches to investigate apoe4 toxicity as part of a five-year project.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.
The firm completed financing actions raising around $1.2 billion in funds that it plans to use to provide financial flexibility and fund corporate objectives.
They collected data on 59 features of more than 100,000 phosphosites and combined those features into a score predictive of a site's functional importance.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
The company said it will use the funds to support development of its structure for lossless ion manipulation (SLIM) ion mobility separations technology.
Waters posted revenues of $577.3 million, short of the average Wall Street estimate of $588.9 million, as soft US pharma sales negatively impacted businesses.
